Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
medical tags : Trial save search
New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 15:00) - hancockjaffe.com
NVNO | $5.13 4.48% 40K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
venovalve symposium topline medical trial
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
NVNO | $5.13 4.48% 40K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
symposium topline medical trial
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
ICCM | $1.22 28K
|
Manufacturing
| Email alert
Add to watchlist
free breast cancer medical trial results
GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: 0.17%
H: 0.0%
C: -0.43%
gammatile tumors for trial
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Published: 2024-03-11 (Crawled : 12:30) - globenewswire.com
DERM | $3.5 -1.13% 48K
|
|
| O: -1.45%
H: 0.88%
C: -0.88%
FBIO | $1.8 2.86% 34K
|
Health Technology
|
| O: -0.48%
H: 2.87%
C: -4.31%
dfd-29 presentation corporation meeting impact medical trial
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
NVNO | $5.13 4.48% 40K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 positive topline meeting trial today
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - hancockjaffe.com
NVNO | $5.13 4.48% 40K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 venovalve positive topline meeting trial today
Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2
Published: 2024-03-01 (Crawled : 23:00) - prnewswire.com
JNJ | News | $149.575 0.31% 2.5M
|
Health Technology
| Email alert
Add to watchlist
hospital pharmaceuticals global medical trial
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Published: 2024-02-20 (Crawled : 14:00) - biospace.com/
NVNO | $5.13 4.48% 40K
|
Manufacturing
|
| O: 2.59%
H: 15.53%
C: 7.18%
enous2024 topline meeting medical trial
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important February 20 Deadline in Securities Class Action - INSP
Published: 2024-02-10 (Crawled : 00:20) - prnewswire.com
BNTX | News | $89.015 1.14% 120K
|
Health Technology
| Email alert
Add to watchlist
INSP | $227.69 1.1% 62K
|
Health Technology
| Email alert
Add to watchlist
MRCY | News | $27.575 0.2% 76K
|
Electronic Technology
| Email alert
Add to watchlist
inspire deadline medical trial
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
Published: 2024-02-05 (Crawled : 12:30) - globenewswire.com
MBOT | $0.885 -0.28% 46K
|
Health Technology
|
| O: 1.65%
H: 1.63%
C: 0.81%
fda approval medical application trial
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSP
Published: 2024-02-03 (Crawled : 04:20) - prnewswire.com
INSP | $227.69 1.1% 62K
|
Health Technology
| Email alert
Add to watchlist
EH | $16.77 -1.35% 440K
|
Technology Services
| Email alert
Add to watchlist
inspire deadline medical trial
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
Published: 2024-01-26 (Crawled : 13:00) - globenewswire.com
FEMY | $1.29 1.58% 190K
|
Manufacturing
|
| O: 2.4%
H: 1.23%
C: -0.28%
health innovation care research women medical trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages General Motors Company Investors to Secure Counsel Before Important Deadline in Securities Class Action - GM
Published: 2024-01-18 (Crawled : 02:00) - prnewswire.com
INSP | $227.69 1.1% 62K
|
Health Technology
|
| O: 1.48%
H: 2.16%
C: 1.51%
GM | News 4 d | $45.19 4.58% 14M
|
Consumer Durables
|
| O: 0.83%
H: 0.17%
C: -2.04%
DADA | News | $1.935 1.84% 550K
|
Technology Services
|
| O: 1.33%
H: 21.05%
C: 18.42%
company deadline trial
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
Published: 2023-12-28 (Crawled : 13:30) - globenewswire.com
ICU A | $0.4448 2.07% 700K
|
|
| O: -7.0%
H: 5.15%
C: 1.15%
device kidney medical trial
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Inspire Medical Systems, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INSP
Published: 2023-12-28 (Crawled : 03:00) - prnewswire.com
DRVN | $14.835 2.95% 310K
|
|
| O: -0.5%
H: 2.71%
C: 2.71%
INSP | $227.69 1.1% 62K
|
Health Technology
|
| O: 0.44%
H: 1.23%
C: -0.26%
inspire deadline medical trial
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
Published: 2023-12-20 (Crawled : 20:00) - biospace.com/
CELZ | $4.8301 6.5K
|
|
| O: -1.07%
H: 43.17%
C: 1.08%
fda back granted clearance medical technology trial
Spectral Medical Provides Tigris Trial Update
Published: 2023-12-14 (Crawled : 13:00) - globenewswire.com
BAX | $40.755 0.88% 450K
|
Health Technology
|
| O: 1.7%
H: 2.44%
C: 1.78%
update medical trial
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
Published: 2023-12-08 (Crawled : 13:00) - globenewswire.com
SGHT | $5.63 4.84% 72K
|
|
| O: -2.26%
H: 13.51%
C: 10.81%
omni publication sciences system technology trial
Spectral Medical Provides November Tigris Trial Update
Published: 2023-12-04 (Crawled : 13:00) - globenewswire.com
BAX | $40.755 0.88% 450K
|
Health Technology
|
| O: -0.77%
H: 2.51%
C: 1.71%
update medical trial
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.355 88.4% 34M
|
Finance
EDBL | News | $6.75 79.52% 1.5M
|
CZOO | $8.77 75.75% 11M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
CMAX | $4.12 28.35% 65K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.